NCT06571487

Recruiting

Growth Hormone Resistance of Beta-cells A

University of Missouri-Columbia Source

Compare

Other study identifiers

Sponsor study identifier

2111127-A

Study Type

observational

Estimated enrollment

30

Locations

1 country

Sites

1

Timeline

Study Start

October 22, 2025

Actual (reported)

Primary Completion

September 1, 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

September 1, 2030

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Brief Summary

The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a personal history of gestational diabetes (high blood sugar in pregnancy) at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: recruiting
Estimated enrollment: 30 participants
Study completion date: September 1, 2030
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
August 22, 2024
Actual (reported)
First Posted
August 26, 2024
Actual (reported)
Study Start
October 22, 2025
Actual (reported)
Primary Completion
September 1, 2028
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
September 1, 2030
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated: May 11, 2026
Status Verified: April 2026
Last Update Submitted: May 5, 2026

Conditions

Gestational Diabetes Healthy Obesity

Outcome Measures

Primary Outcomes (1)

Beta-cell function
Insulin secretion rate in relationship to plasma glucose
before and 7 days after rhGH administration

Study Arms (2)

Women with a history of gestational diabetes mellitus

Women without a history of gestational diabetes mellitus

Eligibility Criteria

Age18 Years - 45 Years

Sexfemale

Healthy VolunteersYes

Age GroupsAdult (18-64)

Sampling MethodNon-Probability Sample

Study Population

The study population will consist of women ages 18-45 with and without a history of gestational diabetes mellitus.

You may qualify if:

Singleton, full term pregnancy within the past 5 years

Sponsors & Collaborators

University of Missouri-Columbia
Otherlead

Study Sites (1)

University of Missouri School of Medicine

Columbia, Missouri, 65212, United States

RECRUITING

Bettina MittendorferCONTACT573-882-9377 b.mittendorfer@missouri.edu

MeSH Terms

Conditions

Diabetes, GestationalObesity

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and Symptoms

Study Officials

Bettina Mittendorfer, PhD
University of Missouri-Columbia
PRINCIPAL INVESTIGATOR

Central Study Contacts

Amanda Heider

CONTACT

573-884-6852 ahmc4@health.missouri.edu

Vasavi Shabrish, PhD

CONTACT

v.shabrish@missouri.edu

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Senior Associate Dean for Research; Professor, Medicine & Nutrition; NextGen Director of Clinical and Translational Sciences Unit

Study Record Dates

First Submitted

August 22, 2024

First Posted

August 26, 2024

Study Start

October 22, 2025

Actual (reported)

Primary Completion

September 1, 2028

NCT01344278

Diabetes Prevention Strategies in Women With Gestational Diabetes Mellitus (GDM)

Not ApplicableCompleted

NCT05219799

Sex Disparities in Hypoxic Vasodilation and Impact of Obesity

Early Phase 1Recruiting

NCT05295940

A Study of LY3841136 in Healthy and Overweight Participants

Phase 1Completed

NCT00001722

Fat Tissue Microperfusion to Measure Leptin Secretion and Its Relations With Fat Breakdown in Humans

Completed

NCT07400679

A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity

Phase 1Completed

NCT04946552

Sympathetic Activation in Obesity

Not ApplicableCompleted

Body mass index ≥18.5 kg/m2 and \<45.0 kg/m2

Gestational Diabetes Group: History of gestational diabetes in the most recent pregnancy

Control Group: no history of gestational diabetes

You may not qualify if:

Pregnant, planning to become pregnant during the study, or breastfeeding
Current diagnosis or history of type 1 or type 2 diabetes
Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
History of bariatric surgery
Known, uncontrolled hypothyroidism
History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
Current cancer or cancer that has been in remission less than 5 years
First degree relative with diabetes diagnosis
Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day
Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration
Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent

Contact the study team to confirm eligibility.

Pathological Conditions, Signs and Symptoms

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

September 1, 2030

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated

May 11, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing: Will share
Time Frame: 5 years after completion of the study

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT06571487
Data provider: ClinicalTrials.gov
Source updated: 2026-05-11
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:39:01 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Women with a history of gestational diabetes mellitus

Women without a history of gestational diabetes mellitus

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations